CRF Health
announced that the company has recently completed the ePRO vendor certification program for use of the
EXA
cerbations of
C
hronic Pulmonary Disease
T
ool (EXACT). The EXACT is a patient-reported outcome (PRO) measure designed to standardize the method for evaluating the frequency, severity, and duration of acute exacerbations of chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) in U.S., as well as international based studies and clinical trials. Developed by
United BioSource Corporation
(UBC) through a multi-sponsor consortium approach involving input from clinical and methodological advisors and involvement of the U.S. Food and Drug Administration (FDA), the EXACT is a standardized tool for measuring exacerbations of COPD.
CRF Health has achieved certification for two devices currently in use with many ongoing projects; the HTC® HD2 and the HTC® Touch 2, which both use the Windows® Mobile operating system. “This certification allows CRF Health to meet the needs of our client base with regard to using the EXACT measure in their respiratory clinical studies, while giving our sponsor-clients confidence that the data collected via CRF Health’s ePRO solutions will be captured in a consistent and proven manner,” stated John Jordan, Senior VP of eClinical Technology for CRF Health.
When collecting EXACT data, clients have the option of a smaller screen device (HTC® Touch 2) or a larger screen (HTC® HD2), depending on the design of the clinical study and the clients’ preferences.
“We are pleased to certify CRF Health on the electronic delivery of the EXACT and to continue our work with them in the use of the EXACT and other PROs in all types of clinical studies,” said Sonya Eremenco, ePRO Manager at United BioSource Corporation and EXACT Certification Program Manager.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.